Cite

    Martina Gruber et al.. “P300 is upregulated by docetaxel and is a target in chemoresistant prostate cancer.” Endocrine-related cancer, vol. 27, no. 3, 2020, pp. 187–198. http://access.bl.uk/ark:/81055/vdc_100120090798.0x00003f